Skip to content

GoodRx Holdings, Inc. GDRX Prescription reimbursement assets

Prescription reimbursement assets at other companies

Albertsons Companies logo
Albertsons CompaniesACI
$519.8M+12.0%
Veracyte logo
VeracyteVCYT
$1.1M-78.4%
NovoCure logo
NovoCureNVCR
$53.13M+56.1%
XER
Xeris Biopharma Holdings, Inc.XERS
$45.49M+48.0%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$619.6M-15.0%
SoundHound AI, Inc. logo
SoundHound AI, Inc.SOUN
$32.75M+52.9%

Other financials

Income statement

See full
Revenue$194.0M-4.4%
Gross profit$173.9M-8.3%
Operating income$14.0M-40.1%
Net income$1.2M-89.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$235.7M-21.7%
Total debt$541.4M0.0%
Total equity$622.0M-4.9%
Total assets$2.0B+56.0%

Cash flow

See full
Operating cash flow$11.8M+25.8%
CapEx$1.1M+700%
Free cash flow$10.7M+15.4%

Valuation

See full
Market cap$911.04M-44.5%
Enterprise value$1.22B-35.4%
P/E44.3×-13.4×
P/S1.2×-0.9×

Profitability

See full
Gross margin91.8%-2.0pp
Operating margin9.9%-0.3pp
Net margin2.6%-1.0pp
FCF margin21%+2.3pp

Returns & leverage

See full
Return on equity3.2%-1.2pp
Debt / equity0.9×0.0×
Current ratio1.5×-3.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept gdrx:PrescriptionReimbursementAssetsCurrent.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s prescription reimbursement assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s prescription reimbursement assets?
GoodRx Holdings, Inc. (GDRX) reported prescription reimbursement assets of $753.53M in Q1 2026.
What does prescription reimbursement assets mean?
This represents the current receivables or amounts due from pharmacy benefit managers (PBMs) or other partners related to prescription transactions facilitated by the platform. It reflects the company's short-term claims on cash for services rendered in the prescription pricing and discount ecosystem. Monitoring this balance helps assess the timing of cash inflows and the credit risk associated with key distribution partners.